The convergence of this epidemiological evidence with our experimental data thus provides a compelling rationale for exploring hormone-based therapies, particularly those targeting the TGF-β signaling and ECM dysregulation central to FECD. The gene discussed is TGFB1; the disease is Fuchs endothelial corneal dystrophy.